ES2157981T3 - Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad. - Google Patents

Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.

Info

Publication number
ES2157981T3
ES2157981T3 ES94910854T ES94910854T ES2157981T3 ES 2157981 T3 ES2157981 T3 ES 2157981T3 ES 94910854 T ES94910854 T ES 94910854T ES 94910854 T ES94910854 T ES 94910854T ES 2157981 T3 ES2157981 T3 ES 2157981T3
Authority
ES
Spain
Prior art keywords
protein products
bactericidic
therapeutic uses
permeability
permeability protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910854T
Other languages
English (en)
Spanish (es)
Inventor
Roger G Ii Little
Helene Gazzano-Santoro
James Brian Parent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/030,644 external-priority patent/US5348942A/en
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Application granted granted Critical
Publication of ES2157981T3 publication Critical patent/ES2157981T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES94910854T 1993-03-12 1994-03-11 Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad. Expired - Lifetime ES2157981T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/030,644 US5348942A (en) 1993-03-12 1993-03-12 Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A 1993-07-15 1993-07-15

Publications (1)

Publication Number Publication Date
ES2157981T3 true ES2157981T3 (es) 2001-09-01

Family

ID=26706282

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910854T Expired - Lifetime ES2157981T3 (es) 1993-03-12 1994-03-11 Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.

Country Status (15)

Country Link
US (3) US5639727A (OSRAM)
EP (2) EP1129718A3 (OSRAM)
JP (3) JPH08509703A (OSRAM)
CN (2) CN1105574C (OSRAM)
AT (1) ATE202482T1 (OSRAM)
AU (1) AU684503B2 (OSRAM)
CA (1) CA2157927C (OSRAM)
DE (1) DE69427582T2 (OSRAM)
DK (1) DK0690720T3 (OSRAM)
ES (1) ES2157981T3 (OSRAM)
GR (1) GR3036686T3 (OSRAM)
MX (1) MX9401807A (OSRAM)
NZ (1) NZ263057A (OSRAM)
PT (1) PT690720E (OSRAM)
WO (1) WO1994020128A1 (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
NZ263057A (en) * 1993-03-12 2000-12-22 Xoma Corp Use of bactericidal permeability increasing proteins or derivative for treating chronic inflammatory diseases, neutralising heparin, inhibiting angiogenesis, tumour and epithelial cell proliferation
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU7175694A (en) 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
WO1995008344A1 (en) * 1993-09-22 1995-03-30 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
AU703192B2 (en) * 1994-01-14 1999-03-18 Xoma Corporation Anti-gram-positive bacterial methods and materials
ATE215379T1 (de) * 1994-01-14 2002-04-15 Xoma Technology Ltd Antifungaleverfahren und mitteln
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
EP0824547B1 (en) * 1994-09-15 2003-12-10 XOMA Technology Ltd. Anti-fungal peptides
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DK0914144T3 (da) 1996-05-10 2001-04-09 Univ Texas Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
AU3352799A (en) * 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
US6264596B1 (en) 1997-11-03 2001-07-24 Meadox Medicals, Inc. In-situ radioactive medical device
US5994298A (en) * 1997-12-18 1999-11-30 Tsai; David Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US6964948B2 (en) * 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
US6515104B1 (en) * 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
EP1339424A2 (en) * 2000-12-01 2003-09-03 XOMA Technology Ltd. Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
EP1492874B1 (en) 2002-03-29 2011-01-19 XOMA Technology Ltd. Multigenic vector plasmids and methods for increasing expression of recombinant polypeptides
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
JP5982361B2 (ja) 2010-04-16 2016-08-31 モメンタ ファーマシューティカルズ インコーポレイテッド 組織標的化方法
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
AU2012240206C1 (en) * 2011-04-05 2017-11-23 Children's Medical Center Corporation BPI and its congeners as radiation mitigators and radiation protectors
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
IT201700108102A1 (it) * 2017-09-27 2019-03-27 Univ Degli Studi Padova Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie
WO2019063320A1 (en) 2017-09-27 2019-04-04 Universita' Degli Studi Di Padova COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
EP3566717A1 (en) 2018-05-09 2019-11-13 Universität Regensburg Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
EP0652230B1 (en) * 1987-08-11 2005-12-14 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
CA2082804A1 (en) * 1990-07-27 1992-01-28 Theodore Maione Methods and compositions for treatment of angiogenic diseases
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
EP0576669A4 (en) * 1992-01-16 1996-05-08 Repligen Corp Novel methods and compositions for treatment of angiogenic diseases
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
NZ263057A (en) * 1993-03-12 2000-12-22 Xoma Corp Use of bactericidal permeability increasing proteins or derivative for treating chronic inflammatory diseases, neutralising heparin, inhibiting angiogenesis, tumour and epithelial cell proliferation

Also Published As

Publication number Publication date
CN1124455A (zh) 1996-06-12
JPH08509703A (ja) 1996-10-15
US5639727A (en) 1997-06-17
AU6360594A (en) 1994-09-26
MX9401807A (es) 1995-01-31
CN1478543A (zh) 2004-03-03
US20020090368A1 (en) 2002-07-11
WO1994020128A1 (en) 1994-09-15
AU684503B2 (en) 1997-12-18
DK0690720T3 (da) 2001-08-27
NZ263057A (en) 2000-12-22
ATE202482T1 (de) 2001-07-15
DE69427582T2 (de) 2001-10-04
GR3036686T3 (en) 2001-12-31
PT690720E (pt) 2001-12-28
DE69427582D1 (de) 2001-08-02
EP0690720B1 (en) 2001-06-27
US5807818A (en) 1998-09-15
EP1129718A2 (en) 2001-09-05
CN1105574C (zh) 2003-04-16
HK1014497A1 (en) 1999-09-30
CA2157927C (en) 1999-03-30
EP1129718A3 (en) 2002-05-22
JP2005187480A (ja) 2005-07-14
EP0690720A1 (en) 1996-01-10
CA2157927A1 (en) 1994-09-15
JP2005206606A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
ES2157981T3 (es) Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
ATE431364T1 (de) Inhibitoren der menschlichen elastase von neutrophilen
ATE214924T1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
FI933770A7 (fi) Farmaseuttisia koostumuksia ihotautien hoitamiseen
FI943625A0 (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DE69133485D1 (de) Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
MX9307983A (es) Derivados de aminoacidos de heterociclos como inhibidores de la proteina quinasa c.
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
BG94738A (bg) Използване на разтвор на йод за лечение на заболявания, свързани с йодна недостатъчност
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
DE60108076D1 (de) Protein c derivate
ES1022449Y (es) Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
EP0986392A4 (en) METHOD FOR TREATING CHRONIC PROGRESSIVE VASCULAR DISEASES
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DK113789A (da) Thiosulfinsyrederivater, deres anvendelse til behandling af betaendelsessygdomme samt laegemiddel indeholdende disse stoffer
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 690720

Country of ref document: ES